Cardiac cavernous haemangiomas are rare benign tumours more commonly seen in the right heart; this case demonstrated a LAA cavernous haemangioma, which was unusual.

Primary intracardiac tumours are very rare, with an incidence of 0.02% of which myxomas are the most common.1,2 Commonly affecting the mid-aged female population, myxomas are typically located within the atrium (93%) and rarely within the ventricular systems (6–8%).

Prof William Wijns |PCR Chairman; SFI Professor of Interventional Cardiology, National University of Ireland Galway, Galway, Ireland

Prof Bernard Prendergast | Course Director of PCR London Valves and Co-ordinator for Valves and Structural Activities at PCR; Professor of Interventional Cardiology and Valvular Heart Disease, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

The development of interventional cardiology is inevitably associated with increased dose of ionising radiation for the physician.1 Additionally, physiology-guided myocardial revascularisation is supported by both European and American experts,2,3 but these procedures may increase the total procedure time in addition to increased dose of ionising radiation for the physician.

Transcatheter valve embolisation and migration (TVEM) into the left ventricle (LV) is especially significant and requires conversion to an emergency surgical technique, with unusually high mortality reported.

This document aims to provide an overview of the clinical and regulatory challenges faced in the use of cannabinoid-based products in medicine, without becoming a comprehensive humanity review of the literature on the medical possibilities of cannabinoids.

This article discusses the results published in 2020 and early 2021 from key clinical trials of PARP inhibitors in patients with advanced ovarian cancer in terms of long-term efficacy and survival rates.